-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
“Relying on Precision, Caring for the Future” Business Exchange Conference Held in Zhengzhou
Category:
发布时间：2025-03-26
【概要描述】
With the surging waves of the Yellow River heralding a new journey, the business community gathers in March in the “City of Commerce” to bring together industry leaders. Recently, the “Relying on Precision, Caring for the Future” 2025 Business Exchange Conference, co-hosted by Henan Zhixing Pharmaceutical Co., Ltd., Shijiazhuang Sihua Pharmaceutical Group, and Hebei Yipin Pharmaceutical Co., Ltd., was grandly inaugurated in Zhengzhou. Guests from across the country convened to discuss a new blueprint for the healthy development of the industry.
The surging waves of the Yellow River herald a new journey, as the “City of Commerce” gathers its finest talents in March. Recently, the “Relying on Precision, Caring for the Future” 2025 Business Exchange Conference, co-hosted by Henan Zhixing Pharmaceutical Co., Ltd., Shijiazhuang Sihua Pharmaceutical Group, and Hebei Yipin Pharmaceutical Co., Ltd., was grandly inaugurated in Zhengzhou. Guests from across the country convened to discuss a new blueprint for the healthy development of the industry.
In his address, Qu Benyue, Executive President of Shijiazhuang No.4 Pharmaceutical Group, stated that the company is committed to researching, developing, and manufacturing more “Made-in-China” medicines, upholding its original aspiration and mission of “producing high-quality medicines for the people.” Shijiazhuang No.4 Pharmaceutical remains steadfast in implementing an innovation-driven development strategy, accelerating the integrated development of active pharmaceutical ingredients and finished dosage forms, and focusing on market positioning and R&D in the anesthesia sector. Through continuous technological innovation, the company has successfully launched a number of new products with strong market potential and competitive advantages, including etomidate medium- and long-chain fat emulsion for injection, thereby steadily expanding the geographic reach of its product portfolio. Looking ahead, Shijiazhuang No.4 Pharmaceutical will further strengthen industrial collaboration with a broad range of customers, including Zhixing Pharmaceutical, to contribute the pharmaceutical industry’s strength to the building of a Healthy China.
During the meeting, industry experts provided a systematic analysis of current market conditions and the competitive landscape in the anesthesia sector, while also discussing emerging industry trends. They engaged with attendees in a collaborative exploration of pathways for industry upgrading. Meanwhile, a product manager from the Marketing Center of Shijiazhuang Sihua Pharmaceutical Group shared insights into the company’s innovative development and highlighted key new products, including etomidate medium- and long-chain fat emulsion for injection. This presentation enabled participants to gain a clearer understanding of the company’s strengths and product advantages, thereby further reinforcing their confidence in future collaboration.
A spokesperson for the group stated that this exchange event, by establishing a platform for in-depth dialogue, has not only enhanced stakeholders’ understanding of key products such as etomidate medium- and long-chain fat emulsion for injection, but has also fostered a virtuous cycle of innovation-driven development and market application, thereby injecting new momentum into the industry’s high-quality growth.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091